2024
Characterizing Gabapentinoid Use Among Patients With Isolated Low Back Pain
Maloy G, Halperin S, Ratnasamy P, Grauer J. Characterizing Gabapentinoid Use Among Patients With Isolated Low Back Pain. Global Spine Journal 2024, 15: 1106-1112. PMID: 38270402, PMCID: PMC11571306, DOI: 10.1177/21925682231224390.Peer-Reviewed Original ResearchIsolated low back painLow back painBack painGabapentinoid prescriptionInternational Classification of DiseasesPrimary care physiciansNon-clinical factorsPrescriber specialtyClassification of diseasesPain management physiciansHistory of spinal surgeryEvaluate prescription patternsLBP patientsPatient characteristics predictiveNurse practitionersCare physiciansInternational ClassificationOff-label useSpinal fracturesInsurance typePrescribing gabapentinoidsManaging physicianFemale sexPostoperative painGabapentinoid use
2023
Factors Associated With Increased Opioid Prescriptions Following Anterior Cruciate Ligament Reconstruction in Opioid-Naïve Patients
Yalcin S, Joo P, McLaughlin W, Moran J, Caruana D, Flores M, Grauer J, Medvecky M. Factors Associated With Increased Opioid Prescriptions Following Anterior Cruciate Ligament Reconstruction in Opioid-Naïve Patients. Arthroscopy Sports Medicine And Rehabilitation 2023, 5: 100740. PMID: 37645399, PMCID: PMC10461142, DOI: 10.1016/j.asmr.2023.04.023.Peer-Reviewed Original ResearchAnterior cruciate ligament reconstructionOpioid-naïve patientsOpioid prescriptionsCruciate ligament reconstructionOrthopaedic surgeonsMean MMEOpioid useLigament reconstructionPreoperative diagnosisArthroscopic anterior cruciate ligament reconstructionMedical providersFollowing Anterior Cruciate Ligament ReconstructionOlder ageRetrospective cohort studyCollateral ligament repairSubstance use disordersMean morphineNaïve patientsOpioid dosesPrescriber specialtyCohort studyPatient factorsChronic painAverage MMEPhysician specialtyOpioid Prescription Patterns 90 Days After Arthroscopic Rotator Cuff Repair: A 10-Year National Database Analysis
Day W, Tang K, Joo P, Grauer J, Yalcin S, Wilhelm C, Medvecky M. Opioid Prescription Patterns 90 Days After Arthroscopic Rotator Cuff Repair: A 10-Year National Database Analysis. Orthopaedic Journal Of Sports Medicine 2023, 11: 23259671231159063. PMID: 37056452, PMCID: PMC10087648, DOI: 10.1177/23259671231159063.Peer-Reviewed Original ResearchArthroscopic rotator cuff repairOpioid prescription trendsRotator cuff repairOpioid prescriptionsPrescription trendsCuff repairCurrent prescription patternsPostoperative pain managementElixhauser Comorbidity IndexNational database analysisNational administrative databaseLevel of evidenceRegression analysisMean MMEMore MMEsPostoperative amountPostoperative MMEPostoperative morphineComorbidity indexNaïve patientsPrescriber specialtyAdult patientsPostoperative periodPrescription patternsYounger patients
2019
Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 2305-2314. PMID: 30690529, DOI: 10.1210/jc.2018-02197.Peer-Reviewed Original ResearchConceptsBrand-name useDrug useMedicare AdvantageThyroid hormone replacement therapyLarge administrative claims databaseBeneficiary populationAdministrative claims databaseHormone replacement therapyCertain patient characteristicsMedicare Part DPrescriber specialtyPatient characteristicsPrescriber characteristicsClaims databaseReplacement therapyGeneric levothyroxineWhite raceHealth plansOlder adultsHormone drugsInsurance coverageProduct useLevothyroxineNational dataPart D
2017
Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.
Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.Peer-Reviewed Original ResearchICD9 codesBarcelona Clinic Liver Cancer stageOverall median survival rateInitial dosing regimensLiver Cancer stageMedian survival rateSimilar treatment durationCTP AECOG PSExtrahepatic spreadChild-TurcotteMacrovascular invasionMELD scorePrescriber specialtyReal-world practiceMedian agePharmacy recordsSorafenib exposureBCLC 0Dosing regimensLiver diseaseTumor numberPrescribing practicesHCC patientsCancer stage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply